Hypertension With Left Ventricular Hypertrophy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypertension with left ventricular hypertrophy. 3 active patents protecting 2 drugs from 2+ originators. First major cliff: 2041. Daily refresh.

2
Approved drugs
3
Active US patents
70/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypertension With Left Ventricular Hypertrophy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 2 patents Generic (originally Merck) 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypertension with left ventricular hypertrophy. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cozaar
LOSARTAN POTASSIUM
 Merck & Co. 2 65 — 2041-10-07
Microzide
hydrochlorothiazide
 Generic (originally Merck) 1 75 — 2044-01-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12156869 Cozaar method of use 75 2041-10-07
11878022 Microzide method of use 75 2044-01-23
11890273 Cozaar formulation 55 2041-10-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11890273 Cozaar formulation 55 2041-10-07
11878022 Microzide method of use 75 2044-01-23
12156869 Cozaar method of use 75 2041-10-07

Related